Orphan Drug DesignationKRRO-110 has been granted orphan drug designation by the European Medicines Agency, which is a positive development for its potential treatment of Alpha-1 Antitrypsin Deficiency.
RNA Editing PotentialRNA editing holds significant potential based on preclinical data and Korro is one of the leaders in the field.
Safety ProfileMore than 80% of planned healthy volunteers have now been dosed across multiple single-ascending-dose cohorts, with no treatment-emergent serious adverse events or dose-limiting toxicities observed.